108 related articles for article (PubMed ID: 17854171)
1. Use of drug discovery tools in rational organometallic catalyst design.
Drummond ML; Sumpter BG
Inorg Chem; 2007 Oct; 46(21):8613-24. PubMed ID: 17854171
[TBL] [Abstract][Full Text] [Related]
2. Rational approach to polymer-supported catalysts: synergy between catalytic reaction mechanism and polymer design.
Madhavan N; Jones CW; Weck M
Acc Chem Res; 2008 Sep; 41(9):1153-65. PubMed ID: 18793027
[TBL] [Abstract][Full Text] [Related]
3. High-throughput approaches for the discovery and optimization of new olefin polymerization catalysts.
Murphy V; Bei X; Boussie TR; Brümmer O; Diamond GM; Goh C; Hall KA; Lapointe AM; Leclerc M; Longmire JM; Shoemaker JA; Turner H; Weinberg WH
Chem Rec; 2002; 2(4):278-89. PubMed ID: 12203910
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
Wang XS; Tang H; Golbraikh A; Tropsha A
J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
[TBL] [Abstract][Full Text] [Related]
5. Fuzzy tricentric pharmacophore fingerprints. 2. Application of topological fuzzy pharmacophore triplets in quantitative structure-activity relationships.
Bonachéra F; Horvath D
J Chem Inf Model; 2008 Feb; 48(2):409-25. PubMed ID: 18254617
[TBL] [Abstract][Full Text] [Related]
6. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
7. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
[TBL] [Abstract][Full Text] [Related]
8. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
9. A fully integrated high-throughput screening methodology for the discovery of new polyolefin catalysts: discovery of a new class of high temperature single-site group (IV) copolymerization catalysts.
Boussie TR; Diamond GM; Goh C; Hall KA; LaPointe AM; Leclerc M; Lund C; Murphy V; Shoemaker JA; Tracht U; Turner H; Zhang J; Uno T; Rosen RK; Stevens JC
J Am Chem Soc; 2003 Apr; 125(14):4306-17. PubMed ID: 12670253
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial and computational approaches in structure-based drug design.
Kubinyi H
Curr Opin Drug Discov Devel; 1998 Jul; 1(1):16-27. PubMed ID: 19649785
[TBL] [Abstract][Full Text] [Related]
11. Precision control of radical polymerization via transition metal catalysis: from dormant species to designed catalysts for precision functional polymers.
Ouchi M; Terashima T; Sawamoto M
Acc Chem Res; 2008 Sep; 41(9):1120-32. PubMed ID: 18793026
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
Du QS; Huang RB; Wei YT; Pang ZW; Du LQ; Chou KC
J Comput Chem; 2009 Jan; 30(2):295-304. PubMed ID: 18613071
[TBL] [Abstract][Full Text] [Related]
13. Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR.
Totrov M
Chem Biol Drug Des; 2008 Jan; 71(1):15-27. PubMed ID: 18069986
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
[TBL] [Abstract][Full Text] [Related]
15. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
16. Penultimate effect in ethylene-styrene copolymerization and the discovery of highly active ethylene-styrene catalysts with increased styrene reactivity.
Arriola DJ; Bokota M; Campbell RE; Klosin J; LaPointe RE; Redwine OD; Shankar RB; Timmers FJ; Abboud KA
J Am Chem Soc; 2007 Jun; 129(22):7065-76. PubMed ID: 17489593
[TBL] [Abstract][Full Text] [Related]
17. Metal-organic cooperative catalysis in C-H and C-C bond activation and its concurrent recovery.
Park YJ; Park JW; Jun CH
Acc Chem Res; 2008 Feb; 41(2):222-34. PubMed ID: 18247521
[TBL] [Abstract][Full Text] [Related]
18. Visualization of high-dimensional combinatorial catalysis data.
Suh C; Sieg SC; Heying MJ; Oliver JH; Maier WF; Rajan K
J Comb Chem; 2009; 11(3):385-92. PubMed ID: 19298082
[TBL] [Abstract][Full Text] [Related]
19. Molecule-pharmacophore superpositioning and pattern matching in computational drug design.
Wolber G; Seidel T; Bendix F; Langer T
Drug Discov Today; 2008 Jan; 13(1-2):23-9. PubMed ID: 18190860
[TBL] [Abstract][Full Text] [Related]
20. "Catalysis in a tea bag": synthesis, catalytic performance and recycling of dendrimer-immobilised bis- and trisoxazoline copper catalysts.
Gaab M; Bellemin-Laponnaz S; Gade LH
Chemistry; 2009; 15(22):5450-62. PubMed ID: 19388035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
